<DOC>
	<DOCNO>NCT01404702</DOCNO>
	<brief_summary>Neuroblastoma ( NB ) common extracranial solid tumor child , annual incidence 10.5 per million child le 15 year age . NB account 15 % childhood cancer death . High risk ( HR ) patient carry poor prognosis despite treatment intensive chemotherapy , surgery and/or radiation , autologous bone marrow transplant , treatment cis-retinoic acid . New therapy desperately need patient . Recently , demonstrate HR NB patient benefit anti-GD2 antibody therapy direct immune system NB cell . To explore mean harness immune system attack NB , investigator study combination zoledronic acid ( ZOL ) interleukin-2 ( IL-2 ) . ZOL demonstrate direct anti-neuroblastoma effect laboratory study . ZOL also augment production tumor kill white blood cell call gamma-delta T cell . When used combination IL-2 , ZOL capable elicit potent anti-cancer effect patient , part , via expansion gamma-delta T cell . In present trial investigator aim study tolerability combination ZOL IL-2 pediatric NB patient . Patients also monitor radiologically tumor response therapy . Correlative biological study study ability drug combination elicit production NB kill gamma-delta T cell child .</brief_summary>
	<brief_title>Pilot Study Zoledronic Acid Interleukin-2 Refractory Pediatric Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>All patient must diagnose treatmentrefractory neuroblastoma know curative treatment option . Tumor histology verify diagnosis relapse . Prior enrollment , determination residual disease must perform Patients must Lansky Karnofsky performance scale score ≥ 50 % . Patients must life expectancy ≥ 2 month ( 8 week ) . Total absolute neutrophil count ( ANC ) least 750 , Hgb≥8 grams/dl , plts ≥ 75K . PRBC transfusion allow . Patients bone marrow disease evaluable hematologic toxicity . These patient must peripheral absolute neutrophil count 750 , platelet count ≥ 50K Hgb ≥8 grams/dl . Transfusions permit meet platelet hemoglobin criterion . Creatinine clearance radioisotope GFR &gt; 70mL/min/1.73 m2 serum creatinine base age/gender follow : ≤ 0.8 mg/dL ( patient 2 5 year age ) ≤ 1.0 mg/dL ( patient 6 9 year age ) ≤ 1.2 mg/dL ( patient 10 12 year age ) ≤ 1.4 mg/dL ( female patient ≥ 13 year age ) ≤ 1.5 mg/dL ( male patient 13 15 year age ) ≤ 1.6 mg/dL ( male patient ≥ 16 year age ) Total bilirubin ≤ 2.5 x upper limit normal ( ULN ) age , SGPT ( ALT ) &lt; 2.5 x upper limit normal ( ULN ) age . SOS ( sinusoidal obstruction syndrome , formerly know venoocclusive disease [ VOD ] ) , present , stable improving . Shortening fraction &gt; 27 % echocardiogram , ejection fraction &gt; 55 % radionuclide angiography . No evidence dyspnea rest . If PFTs perform , FEV1/FVC &gt; 60 % pulmonary function test . Patients seizure disorder may enrol anticonvulsant well control . CNS toxicity &lt; Grade 2 . Females childbearing potential must negative pregnancy test . Patients childbearing potential must agree use effective birth control method . Female patient lactate must agree stop breastfeeding . All patient and/or parent legal guardian must sign write informed consent . All institutional requirement human study must meet . Previous treatment antiGD2 interleukin2 therapy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Refractory</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Biological therapy</keyword>
	<keyword>Lymphocytes</keyword>
	<keyword>Cancer</keyword>
	<keyword>Bisphosphonate</keyword>
</DOC>